The debate about the validity of the CLASS gastrointestinal safety study with Pharmacia's COX-2 inhibitor celecoxib (Celebrex®) has resurfaced with an editorial on the issue in the British Medical ...
SAN FRANCISCO & LONDON--(BUSINESS WIRE)--Red Sift, the leading Digital Resilience Platform enabling organizations to see, solve, and secure vulnerabilities in their attack surface, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback